Can rheumatoid arthritis cause fatty liver? Whilst rheumatoid arthritis (RA) does not directly cause fatty liver disease, people with RA face a significantly higher risk of developing non-alcoholic fatty liver disease (NAFLD). This association stems from chronic systemic inflammation, shared metabolic risk factors, and the effects of certain RA medications. Understanding the connection between these conditions is essential for comprehensive care, as both can impact long-term health outcomes. Regular monitoring of liver function forms an important part of routine management for people living with rheumatoid arthritis, particularly those taking disease-modifying drugs.
Summary: Rheumatoid arthritis does not directly cause fatty liver disease, but people with RA have a significantly higher risk of developing non-alcoholic fatty liver disease due to chronic inflammation, shared metabolic risk factors, and certain RA medications.
- Chronic systemic inflammation in RA promotes insulin resistance and altered lipid metabolism, which can lead to hepatic fat accumulation.
- Prevalence of NAFLD in people with RA ranges from approximately 20% to 50%, compared to lower rates in the general population.
- Methotrexate and leflunomide require regular liver function monitoring due to potential hepatotoxicity, with checks every 2–3 months once treatment is stable.
- Shared risk factors include metabolic syndrome, obesity, physical inactivity, type 2 diabetes, and corticosteroid use.
- NICE guidance recommends non-invasive risk scores such as FIB-4 index to identify those requiring further investigation or specialist referral.
- Weight reduction of 7–10% or more, regular physical activity, and minimising alcohol consumption are key management strategies for liver health in RA.
Table of Contents
- Understanding the Link Between Rheumatoid Arthritis and Fatty Liver
- How Rheumatoid Arthritis Medications Affect Liver Health
- Shared Risk Factors for Rheumatoid Arthritis and Fatty Liver Disease
- Recognising Symptoms of Liver Problems in Rheumatoid Arthritis
- Managing Liver Health When You Have Rheumatoid Arthritis
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding the Link Between Rheumatoid Arthritis and Fatty Liver
Rheumatoid arthritis (RA) is a chronic autoimmune condition characterised by inflammation of the joints, but its effects extend beyond the musculoskeletal system. People with RA have a higher risk of developing non-alcoholic fatty liver disease (NAFLD), though the relationship is one of association rather than direct causation.
The connection between RA and fatty liver disease stems primarily from chronic systemic inflammation. In RA, the immune system produces elevated levels of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These inflammatory mediators can affect metabolic processes throughout the body, including hepatic lipid metabolism. Chronic inflammation promotes insulin resistance, which is a key driver of fat accumulation in the liver. Additionally, the inflammatory state in RA can alter the way the body processes and stores fats, potentially contributing to hepatic steatosis (fatty liver).
Research indicates that people with RA have a higher prevalence of NAFLD compared to the general population. Contemporary studies suggest prevalence rates vary widely depending on the population studied and diagnostic methods used, with estimates typically ranging from approximately 20% to 50%. However, it is important to note that RA does not directly cause fatty liver disease—rather, RA creates conditions that may predispose individuals to NAFLD. The relationship is further complicated by shared risk factors such as obesity, metabolic syndrome, reduced physical activity due to joint pain and stiffness, and the effects of certain RA medications.
If NAFLD is suspected in someone with RA, UK guidance (NICE NG49) recommends initial assessment using non-invasive risk scores such as the FIB-4 index or NAFLD Fibrosis Score, which help identify those who may have significant liver fibrosis and require further investigation or specialist referral.
Understanding this association is crucial for comprehensive RA management, as both conditions can significantly impact long-term health outcomes. Regular monitoring of liver function and metabolic health should form part of routine care for people living with rheumatoid arthritis.
How Rheumatoid Arthritis Medications Affect Liver Health
Many disease-modifying antirheumatic drugs (DMARDs) used to treat RA require careful monitoring due to their potential effects on the liver. Methotrexate, the first-line conventional synthetic DMARD (csDMARD) for RA, is perhaps the most well-known medication requiring liver surveillance. At the low doses used in RA, methotrexate works primarily through anti-inflammatory mechanisms involving adenosine signalling pathways, rather than the dihydrofolate reductase inhibition seen at higher anti-cancer doses. Methotrexate can cause elevated liver enzymes (transaminases) in approximately 13–20% of patients, and in rare cases, may lead to hepatic fibrosis or cirrhosis with long-term use.
UK guidance (BSR DMARD monitoring and product information) recommends regular monitoring of liver function tests. For methotrexate and similar csDMARDs, this typically involves full blood count, renal function, and liver function tests every 1–2 weeks initially until the dose and disease are stable, then monthly for three months, and thereafter every 2–3 months during stable treatment. Monitoring should be repeated after any dose increase. Patients are advised to avoid or strictly limit alcohol consumption whilst taking methotrexate, as this significantly increases the risk of liver damage. Folic acid supplementation, usually prescribed alongside methotrexate (typically 5 mg once weekly, taken on a different day), helps mitigate some hepatotoxic effects.
Leflunomide, another csDMARD, carries similar or higher hepatotoxicity risks and requires stricter monitoring: alanine aminotransferase (ALT) should be checked every 2 weeks for the first 6 months, then every 8 weeks thereafter, as per the product information. The combination of leflunomide with methotrexate increases hepatotoxic risk and requires particularly close monitoring. If ALT rises significantly (typically more than twice the upper limit of normal), dose reduction or temporary cessation may be necessary under specialist guidance.
Biological therapies such as TNF inhibitors (etanercept, adalimumab, infliximab) and other biologics (e.g., rituximab, tocilizumab, abatacept) generally have a more favourable liver safety profile than traditional csDMARDs. However, they can occasionally cause transient elevations in liver enzymes and, rarely, autoimmune hepatitis or drug-induced liver injury. Importantly, biologics carry a risk of reactivating hepatitis B virus (HBV). The MHRA recommends screening for hepatitis B (HBsAg and anti-HBc) and hepatitis C before initiating biological therapy, with appropriate antiviral prophylaxis or monitoring for those with evidence of past or current HBV infection.
Targeted synthetic DMARDs (tsDMARDs), including JAK inhibitors (such as tofacitinib, baricitinib, and upadacitinib), can also elevate liver enzymes and require regular liver function monitoring. Dose adjustments may be needed in moderate to severe hepatic impairment.
Non-steroidal anti-inflammatory drugs (NSAIDs), commonly used for symptom relief in RA, can also affect liver function, particularly with long-term use or in patients with pre-existing liver conditions.
Interestingly, whilst some RA medications pose liver risks, effective control of RA inflammation may actually reduce the metabolic disturbances that contribute to fatty liver disease. This highlights the importance of balancing treatment benefits against potential hepatic complications under specialist supervision. Patients should report any suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).
Shared Risk Factors for Rheumatoid Arthritis and Fatty Liver Disease
Several overlapping risk factors contribute to both rheumatoid arthritis and non-alcoholic fatty liver disease, creating a complex interplay that increases vulnerability to both conditions. Understanding these shared factors is essential for comprehensive patient management.
Metabolic syndrome represents a significant common denominator. This cluster of conditions—including central obesity, hypertension, dyslipidaemia, and insulin resistance—is more prevalent in people with RA than in the general population. The chronic inflammation associated with RA contributes to insulin resistance, which in turn promotes hepatic fat accumulation. Research suggests that a substantial proportion of RA patients may have features of metabolic syndrome, though prevalence varies by population and diagnostic criteria, substantially elevating their risk of NAFLD.
Obesity and physical inactivity are particularly relevant shared risk factors. Joint pain, stiffness, and fatigue associated with RA often limit physical activity, potentially leading to weight gain. Excess adipose tissue, especially visceral fat, produces inflammatory cytokines that perpetuate both the inflammatory state in RA and the development of fatty liver disease. The relationship is bidirectional—inflammation promotes weight gain, and excess weight worsens inflammation.
Corticosteroid use, whilst not a primary risk factor for either condition, can exacerbate both. Long-term prednisolone therapy, sometimes necessary for RA management, promotes weight gain, insulin resistance, and altered lipid metabolism—all contributors to NAFLD. NICE guidance (NG100) recommends using the lowest effective dose of corticosteroids for the shortest duration possible, with a treat-to-target strategy aiming to minimise or discontinue glucocorticoids.
Other shared factors include:
-
Type 2 diabetes, which frequently coexists with both conditions
-
Dyslipidaemia, common in RA and a key driver of hepatic steatosis
-
Smoking, which worsens RA disease activity and contributes to metabolic dysfunction
Recognising these interconnected risk factors allows healthcare professionals to implement targeted preventive strategies and holistic management approaches for patients with RA. UK resources such as NHS Live Well guidance on weight management, physical activity, and smoking cessation can support lifestyle modification as part of comprehensive care.
Recognising Symptoms of Liver Problems in Rheumatoid Arthritis
Detecting liver problems in people with rheumatoid arthritis can be challenging, as early-stage liver disease, including fatty liver, is often asymptomatic. Many patients only discover elevated liver enzymes through routine blood monitoring required for their RA medications. Indeed, many cases of drug-induced liver injury are detected biochemically before symptoms appear, underscoring the importance of adhering to monitoring schedules. However, awareness of potential warning signs is crucial for timely intervention.
In the early stages of NAFLD, most individuals experience no symptoms whatsoever. As the condition progresses, some people may notice:
-
Persistent fatigue (though this overlaps with RA symptoms)
-
Vague discomfort in the right upper abdomen
-
Unexplained weight changes
More advanced liver disease may present with:
-
Jaundice (yellowing of the skin and eyes)
-
Dark urine and pale stools
-
Easy bruising or bleeding, indicating impaired clotting function
-
Abdominal swelling (ascites) or visible abdominal veins
-
Confusion or altered mental state (hepatic encephalopathy in severe cases)
Drug-induced liver injury from RA medications may present differently. Patients taking methotrexate, leflunomide, or other DMARDs should be alert to symptoms such as nausea, loss of appetite, unusual tiredness, or abdominal pain, and should report these promptly to their rheumatology team.
Routine monitoring is essential for early detection. Liver function tests (LFTs) measure enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which become elevated when liver cells are damaged. Patients on csDMARDs typically have LFTs checked every 1–2 weeks initially until the dose and disease are stable, then monthly for three months, and thereafter every 2–3 months once stable, as per BSR guidance and product information. Monitoring is repeated after dose changes.
When to contact your GP or rheumatology team urgently (same day):
-
Jaundice (yellowing of skin or eyes)
-
Marked abdominal swelling
-
Confusion or altered mental state
-
Unusual bleeding or bruising
When to contact your GP or rheumatology team routinely:
-
New or worsening abdominal pain
-
Unexplained nausea or vomiting
-
Dark urine persisting beyond dehydration
-
Any concerns about medication side effects
Do not stop your DMARDs abruptly without specialist advice unless you have been specifically instructed to do so due to significant liver enzyme derangement or other serious side effects. Early recognition and investigation of liver abnormalities can prevent progression to more serious hepatic complications and allow for timely adjustment of RA treatment regimens.
Managing Liver Health When You Have Rheumatoid Arthritis
Effective management of liver health in rheumatoid arthritis requires a multifaceted approach combining lifestyle modifications, careful medication monitoring, and regular clinical surveillance. The goal is to control RA whilst minimising hepatic complications and addressing modifiable risk factors for fatty liver disease.
Lifestyle interventions form the cornerstone of NAFLD prevention and management. Weight management through a balanced diet is particularly important—a weight reduction of 7–10% or more is typically required to improve steatohepatitis and fibrosis, whilst a 5–10% reduction can reduce liver fat content. The Mediterranean diet, rich in vegetables, fruits, whole grains, and healthy fats, has shown benefits for both inflammatory conditions and liver health. Where appropriate, referral to a dietitian can support structured weight-loss programmes. Regular physical activity, adapted to individual joint limitations, helps improve insulin sensitivity and reduce hepatic steatosis. Low-impact exercises such as swimming, cycling, or walking are often well-tolerated by people with RA. NHS guidance on physical activity and weight management can provide additional support.
Alcohol consumption should be minimised or avoided entirely, particularly for patients taking methotrexate, leflunomide, or other potentially hepatotoxic medications. The UK Chief Medical Officers' guidelines recommend not regularly drinking more than 14 units per week, spread over three or more days, with several alcohol-free days each week. However, stricter limits or complete abstinence may be appropriate for those with RA on hepatotoxic drugs—discuss this with your rheumatology team, as local advice may vary.
Medication management requires close collaboration with your rheumatology team. This includes:
-
Attending all scheduled blood monitoring appointments
-
Reporting any new symptoms promptly
-
Never adjusting DMARD doses without medical advice
-
Ensuring folic acid supplementation is taken as prescribed (for methotrexate users)
-
Discussing any over-the-counter medications or supplements, as some can interact with RA drugs or affect liver function
-
Reporting suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
Regular monitoring and investigations as recommended by NICE guidance (NG49) for NAFLD typically include liver function tests and, where NAFLD is suspected, non-invasive risk stratification. This involves calculating the FIB-4 index or NAFLD Fibrosis Score using age, liver enzymes, and platelet count. Age-adjusted thresholds help identify low, indeterminate, or high risk of advanced fibrosis:
-
For those under 65 years: FIB-4 <1.3 suggests low risk; 1.3–2.67 is indeterminate; >2.67 suggests high risk
-
For those aged 65 and over: FIB-4 <2.0 suggests low risk; higher thresholds apply
If the initial score suggests indeterminate or high risk, a second-line test such as the Enhanced Liver Fibrosis (ELF) blood test may be used (a score of ≥10.51 suggests advanced fibrosis). Liver ultrasound or specialised tests such as FibroScan (transient elastography) may also be used to assess liver stiffness and fat content.
Referral to hepatology services is recommended if:
-
FIB-4 or NAFLD Fibrosis Score suggests high risk of advanced fibrosis
-
ELF test is positive (≥10.51)
-
There is suspected advanced liver disease or diagnostic uncertainty
-
Liver function tests remain persistently abnormal despite investigation and management
Managing comorbidities such as type 2 diabetes, hypertension, and dyslipidaemia is essential, as these conditions contribute to both RA complications and liver disease progression. Your GP and rheumatology team should work together to optimise management of these interconnected conditions, ensuring a holistic approach to your long-term health and wellbeing.
Frequently Asked Questions
Does rheumatoid arthritis directly cause fatty liver disease?
No, rheumatoid arthritis does not directly cause fatty liver disease, but it creates conditions that significantly increase the risk of developing non-alcoholic fatty liver disease (NAFLD). The chronic systemic inflammation in RA promotes insulin resistance and alters lipid metabolism, which can lead to fat accumulation in the liver.
How often do I need liver function tests if I'm taking methotrexate for rheumatoid arthritis?
Liver function tests are typically required every 1–2 weeks initially until your dose and disease are stable, then monthly for three months, and thereafter every 2–3 months during stable treatment. Monitoring should be repeated after any dose increase, as methotrexate can affect liver enzymes in approximately 13–20% of patients.
Can I drink alcohol if I have rheumatoid arthritis and take medication for it?
Alcohol should be minimised or avoided entirely, particularly if you take methotrexate or leflunomide, as it significantly increases the risk of liver damage. Discuss your individual situation with your rheumatology team, as stricter limits or complete abstinence may be appropriate depending on your medications and liver health.
What's the difference between fatty liver caused by inflammation and fatty liver from other causes?
Non-alcoholic fatty liver disease (NAFLD) in people with rheumatoid arthritis is influenced by chronic systemic inflammation, which promotes insulin resistance and altered lipid metabolism, in addition to traditional risk factors such as obesity and metabolic syndrome. The inflammatory cytokines produced in RA can directly affect hepatic fat metabolism, creating a distinct pathway compared to NAFLD in people without inflammatory conditions.
What symptoms should make me contact my doctor urgently about possible liver problems?
Contact your GP or rheumatology team urgently (same day) if you develop jaundice (yellowing of skin or eyes), marked abdominal swelling, confusion or altered mental state, or unusual bleeding or bruising. These symptoms may indicate serious liver complications requiring immediate medical assessment.
Will controlling my rheumatoid arthritis help protect my liver?
Yes, effective control of RA inflammation may actually reduce the metabolic disturbances that contribute to fatty liver disease, despite some RA medications posing liver risks. This highlights the importance of balancing treatment benefits against potential hepatic complications under specialist supervision, with regular monitoring to ensure both conditions are optimally managed.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
